###begin article-title 0
###xml 97 105 <span type="species:ncbi:9606">Patients</span>
Serum Lipopolysaccharide Binding Protein Levels Predict Severity of Lung Injury and Mortality in Patients with Severe Sepsis
###end article-title 0
###begin p 1
Members of the GRECIA and GEN-SEP groups are listed in the Acknowledgments.
###end p 1
###begin p 2
Conceived and designed the experiments: JV LPM EE CF JB AM MM LB AA RMK. Performed the experiments: EE JB AM MM LB. Analyzed the data: JV LPM CF SB MM AA RMK. Contributed reagents/materials/analysis tools: LPM EE JB AM SB MM. Wrote the paper: JV LPM CF SB LB AA RMK. Got funding, participated in the data collection and measurements: JV. Got funding: LP CF JB. Participated in data collection and measurements and got funding: EE. Participated in the data collection and measurements: SB.
###end p 2
###begin title 3
Background
###end title 3
###begin p 4
###xml 65 73 <span type="species:ncbi:9606">patients</span>
###xml 250 258 <span type="species:ncbi:9606">patients</span>
There is a need for biomarkers insuring identification of septic patients at high-risk for death. We performed a prospective, multicenter, observational study to investigate the time-course of lipopolysaccharide binding protein (LBP) serum levels in patients with severe sepsis and examined whether serial serum levels of LBP could be used as a marker of outcome.
###end p 4
###begin title 5
Methodology/Principal Findings
###end title 5
###begin p 6
###xml 407 410 401 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vs.</italic>
###xml 435 436 423 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 510 513 496 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vs.</italic>
###xml 538 539 518 519 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 574 577 552 555 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vs.</italic>
###xml 725 728 691 694 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">vs.</italic>
###xml 752 753 712 713 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 876 877 836 837 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 79 87 <span type="species:ncbi:9606">patients</span>
###xml 671 679 <span type="species:ncbi:9606">patients</span>
###xml 692 700 <span type="species:ncbi:9606">patients</span>
LBP serum levels at study entry, at 48 hours and at day-7 were measured in 180 patients with severe sepsis. Data regarding the nature of infections, disease severity, development of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), and intensive care unit (ICU) outcome were recorded. LBP serum levels were similar in survivors and non-survivors at study entry (117.4+/-75.7 microg/mL vs. 129.8+/-71.3 microg/mL, P = 0.249) but there were significant differences at 48 hours (77.2+/-57.0 vs. 121.2+/-73.4 microg/mL, P<0.0001) and at day-7 (64.7+/-45.8 vs. 89.7+/-61.1 microg/ml, p = 0.017). At 48 hours, LBP levels were significantly higher in ARDS patients than in ALI patients (112.5+/-71.8 microg/ml vs. 76.6+/-55.9 microg/ml, P = 0.0001). An increase of LBP levels at 48 hours was associated with higher mortality (odds ratio 3.97; 95%CI: 1.84-8.56; P<0.001).
###end p 6
###begin title 7
Conclusions/Significance
###end title 7
###begin p 8
###xml 92 100 <span type="species:ncbi:9606">patients</span>
Serial LBP serum measurements may offer a clinically useful biomarker for identification of patients with severe sepsis having the worst outcomes and the highest probability of developing sepsis-induced ARDS.
###end p 8
###begin title 9
Introduction
###end title 9
###begin p 10
###xml 162 165 162 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Friedman1">[1]</xref>
###xml 167 170 167 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Engel1">[2]</xref>
###xml 506 509 506 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Villar1">[3]</xref>
###xml 510 513 510 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Shapiro1">[8]</xref>
###xml 801 804 801 804 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Schumann1">[9]</xref>
###xml 946 950 946 950 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Dentener1">[10]</xref>
###xml 1029 1033 1029 1033 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Vreugdenhil1">[11]</xref>
###xml 1229 1233 1229 1233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Grunwald1">[12]</xref>
###xml 1235 1239 1235 1239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Prucha1">[13]</xref>
###xml 1323 1327 1323 1327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Cohen1">[14]</xref>
###xml 1528 1532 1524 1528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Gallay1">[15]</xref>
###xml 1534 1538 1530 1534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Gani1">[16]</xref>
###xml 1619 1622 1611 1614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Salluh1">[5]</xref>
###xml 1624 1628 1616 1620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Prucha1">[13]</xref>
###xml 1630 1634 1622 1626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Opal1">[17]</xref>
###xml 1728 1732 1720 1724 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Schrder1">[18]</xref>
###xml 1869 1873 1861 1865 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Prucha1">[13]</xref>
###xml 1875 1879 1867 1871 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Gani1">[16]</xref>
###xml 1880 1884 1872 1876 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Sakr1">[22]</xref>
###xml 2102 2106 2094 2098 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Prucha1">[13]</xref>
###xml 2108 2111 2100 2103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Lee1">[6]</xref>
###xml 2112 2116 2104 2108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Sakr1">[22]</xref>
###xml 2166 2170 2158 2162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Gani1">[16]</xref>
###xml 2172 2176 2164 2168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Opal1">[17]</xref>
###xml 2178 2182 2170 2174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Sablotzki1">[19]</xref>
###xml 2183 2187 2175 2179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Gani2">[21]</xref>
###xml 657 668 <span type="species:ncbi:9606">participant</span>
###xml 766 774 <span type="species:ncbi:9606">patients</span>
###xml 1442 1448 <span type="species:ncbi:9606">humans</span>
###xml 1806 1814 <span type="species:ncbi:9606">patients</span>
###xml 2074 2082 <span type="species:ncbi:9606">patients</span>
Sepsis remains a major challenge in critical care medicine. It is the leading cause of death and its mortality has not decreased substantially in the past decade [1], [2]. An explosion of information regarding the inflammatory response to sepsis has prompted a search for biomarkers that help elucidate molecular pathways that are important in the pathogenesis of the septic process and acute lung injury, that predict outcome, and that may serve as surrogate indicators of potential benefits of therapies [3]-[8]. However, there is not convincing evidence to support the clinical use of any specific marker. Lipopolysaccharide binding protein (LBP), a key participant in the inflammatory response to infection, may be a useful marker for diagnosis and prognosis of patients with bacterial infections [9]. LBP is a type I acute phase response protein that is produced by hepatocytes, respiratory epithelial cells and a myriad of other cell types [10], and enhances the recognition of endotoxin and pathogens by the immune system [11]. LBP binds to Gram-negative bacteria via the lipid A part of the lipopolysaccharide (LPS) which mediates its binding to the CD14 cellular receptor molecule presented by monocytes and macrophages [12], [13]. Binding of LPS activates monocyte/macrophage system cells via Toll-like receptors [14], resulting in the production of pro-inflammatory cytokines that aggravate the clinical presentation of sepsis. In humans, LBP is constitutively present at a mean serum concentration of 5-20 microg/mL [15], [16], reaching peak levels higher than 200 microg/mL during the acute-phase reaction [5], [13], [17]. LBP also mediates the immune response to diverse pathogens including Gram-positive bacteria [18]. Thus, several studies have reported increased LBP serum levels in adult patients with sepsis caused by bacterial and fungal infections [13], [16]-[22]. However, some of those studies have shown conflicting results and others failed to show any correlation between blood levels and disease severity, most likely due to the limited number of patients with severe sepsis [13], [6]-[22] and/or the absence of follow-up LBP measurements [16], [17], [19]-[21].
###end p 10
###begin p 11
###xml 52 60 <span type="species:ncbi:9606">patients</span>
###xml 566 574 <span type="species:ncbi:9606">patients</span>
In this study, using a large, multicenter cohort of patients meeting the international criteria for severe sepsis, we hypothesized that the pattern of LBP serum levels during the first week of severe sepsis development is a marker of severity and prognosis. The goals of this study were to determine: (i) whether there is a different pattern of LBP serum levels between survivors and non-survivors; (ii) the utility of monitoring LBP serum changes within the first 7 days of severe sepsis as a predictor of outcome, and (iii) whether LBP serum levels differ between patients who developed different degrees of lung injury.
###end p 11
###begin title 12
Materials and Methods
###end title 12
###begin title 13
Objectives
###end title 13
###begin p 14
###xml 51 59 <span type="species:ncbi:9606">patients</span>
###xml 194 202 <span type="species:ncbi:9606">patients</span>
We analyzed the time-course of LBP serum levels in patients with severe sepsis to investigate the hypothesis that serial serum levels of LBP could be used as a marker of severity and outcome in patients with severe sepsis.
###end p 14
###begin title 15
Ethics
###end title 15
###begin p 16
###xml 253 260 <span type="species:ncbi:9606">patient</span>
The study was approved by the Ethics Committees for Clinical Research of the Hospital Universitario NS de Candelaria in Tenerife, Spain, and of the Hospital Universitario Rio Hortega in Valladolid, Spain. Written informed consent was obtained from each patient or an appropriate proxy.
###end p 16
###begin title 17
###xml 0 12 <span type="species:ncbi:9606">Participants</span>
Participants
###end title 17
###begin p 18
###xml 168 172 168 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Levy1">[23]</xref>
###xml 586 590 586 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Levy1">[23]</xref>
###xml 715 719 715 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Levy1">[23]</xref>
###xml 721 725 721 725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Garner1">[24]</xref>
###xml 72 80 <span type="species:ncbi:9606">patients</span>
###xml 345 353 <span type="species:ncbi:9606">patients</span>
###xml 437 445 <span type="species:ncbi:9606">patients</span>
###xml 1222 1230 <span type="species:ncbi:9606">Patients</span>
###xml 1326 1334 <span type="species:ncbi:9606">Patients</span>
###xml 1483 1491 <span type="species:ncbi:9606">patients</span>
###xml 1684 1692 <span type="species:ncbi:9606">Patients</span>
This multicenter, prospective, observational study included consecutive patients older than 18 years old fulfilling the International Sepsis Criteria for severe sepsis [23] admitted between April 2003 and March 2006 into a network of Spanish intensive care units (ICUs) (see appendix for a list of participating centers). We chose to study only patients with severe sepsis to guarantee severity of illness and a high risk for death. All patients were screened for severe sepsis on ICU admission and daily thereafter. Severe sepsis was defined as sepsis complicated by organ dysfunction [23]. We considered sepsis as a clinical syndrome defined by the presence of both infection and a systemic inflammatory response [23], [24]. Sepsis was microbiologically documented or clinically suspected as a result of the presence of white blood cells in a normally sterile body fluid, a perforated viscus, chest X-ray consistent with pneumonia and associated with purulent tracheal secretion, or other clinical syndromes associated with a high probability of infection. Clinically documented infection was defined by the presence of gross pus or an abscess, but no microbiological confirmation because of ongoing antibiotic therapy. Patients were enrolled into this study within the first 24 hours of meeting criteria for severe sepsis. Patients in whom decisions to withhold or withdraw life sustaining treatment were established within the first 24 hours of ICU admission, were excluded. All patients were screened on a daily basis for the presence of clinical and analytical signs of sepsis and, when indicated, cultures, biopsy or aspiration of the potentially infected sites were obtained. Patients were followed until ICU discharge or death.
###end p 18
###begin p 19
###xml 568 569 568 569 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 592 593 592 593 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 622 623 622 623 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 638 639 638 639 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 899 903 895 899 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Hebert1">[25]</xref>
###xml 917 925 <span type="species:ncbi:9606">patients</span>
As a general approach, and for the purpose of this prospective, observational, multicenter, cohort study, all participating physicians were urged to administer broad-spectrum antimicrobial agents in a timely manner, ensure early identification of causative microorganism, intravenous antibiotics as soon as sepsis was suspected or recognized, and to optimize antibiotic selection and timely administration on the basis of the antibiogram. For the ventilatory management, a tidal volume of 5-9 mL/kg predicted body weight at a ventilatory rate to maintain adequate PaCO2, and with PEEP and FiO2 combinations to maintain PaO2>60 mmHg or SpO2>90% were recommended. Fluid resuscitation and vasopressor administration were individualized. The goal was to maintain a systolic blood pressure >/=90 mmHg or a mean arterial pressure of >/=65 mmHg. It was recommended to maintain hemoglobin between 7-10 g/dl [25]. None of the patients in this cohort received activated protein C or low doses of corticosteroids as an adjunctive treatment.
###end p 19
###begin title 20
Data collection
###end title 20
###begin p 21
###xml 388 392 388 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Knaus1">[26]</xref>
###xml 617 621 617 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Bernard1">[27]</xref>
###xml 726 730 726 730 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Vincent1">[28]</xref>
###xml 398 406 <span type="species:ncbi:9606">patients</span>
All data were collected on standardized forms by the clinicians responsible for the study in each ICU. Data collection included demographics, diagnoses, comorbidities, source of sepsis and isolated pathogens. Clinical and laboratory data needed to calculate the Acute Physiology and Chronic Health Evaluation (APACHE) II score were collected within the first 24 hours after ICU admission [26]. All patients enrolled in the present study were followed prospectively for the development of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS), as defined by the American-European Consensus Conference [27]. In addition, number of organ failures included in the Sequential Organ Failure Assessment (SOFA) scale [28], date and time of inclusion into the study (fulfilled the criteria for severe sepsis), ICU and hospital length of stay, and ICU, hospital and 28-day mortality were recorded.
###end p 21
###begin title 22
Blood sampling and laboratory analyses
###end title 22
###begin p 23
###xml 878 879 858 859 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 194 201 <span type="species:ncbi:9606">patient</span>
###xml 1231 1238 <span type="species:ncbi:9606">patient</span>
###xml 1343 1351 <span type="species:ncbi:9606">patients</span>
Blood samples (5 mL) were collected within 24 hours of meeting severe sepsis criteria (baseline). Additional blood samples were obtained at 48 hours and at 7 days after study entry, only if the patient remained hospitalized into the ICU. Samples were centrifuged at 4degreesC for 10 min at 3200 rpm within 35 min after sampling. Three aliquots of serum were collected in cryovials and frozen and stored at -80degreesC. Participating centers shipped the tubes on dry ice to the research laboratory of the coordinating center. Serum LBP was assayed using a commercially available chemoluminescence fully automated immunoassay in an Immulite 1000 analyzer (Diagnostics Products Corporation, Siemens Medical Solutions, Germany). As stated by the manufacturer, the lower assay limit for the LBP assay was 0.2 microg/ml, and the calibration ranged was up to 200 microg/ml, having a 103 linear dynamic range. The described manufacturer within-run intra-sample coefficient of variation ranged from uppermost values of 5,8% for mean concentrations of 14 microg/ml to 3.3% for a concentration of 43 microg/ml. A dilution series was performed for those samples with initial values above the range limit. Single LBP serum measurements in each patient were determined by the same investigator (MM) who was blinded to the clinical parameters and outcome of patients.
###end p 23
###begin p 24
###xml 84 92 <span type="species:ncbi:9606">patients</span>
We chose to test several markers within the inflammatory cascade in a subset of 107 patients in whom adequate serum was available. We measured four biomarkers that have pathogenetic basis in sepsis and ALI/ARDS [interleukin (IL)-6, IL-1-beta, IL-10, and C-reactive protein (CRP)] at study entry, at 48 h and at 7 days. Biomarkers levels were measured in duplicate using a commercial kit according to manufacturer's instructions: IL-6, IL-1-beta, and IL-10 (Siemens Medical Solutions Diagnostics, Caernarfon, UK) in an Immulite analyzer, and CRP (Roche Diagnostic, Basilea, Switzerland) in a Hitachi 917 analyzer.
###end p 24
###begin title 25
Statistical analysis
###end title 25
###begin p 26
###xml 1420 1421 1418 1419 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 918 926 <span type="species:ncbi:9606">patients</span>
Continuous variables are described as either a mean+/-standard deviation (SD), or as a median with interquartile range (IQR). Serum levels among different groups were compared by ANOVA or Student t-test. Categorical variables were compared using the Pearson's chi-square test. A logistic regression model with backwards elimination was used to predict disease outcomes by the variation of LBP levels at 48 hours (transformed into a simple 2 status categorical variable: increase or no-increase), adjusting for age, gender, number of organ failures, ARDS and APACHE II score. To compare the evolution of LBP and IL-6, IL-1-beta, IL-10, and RCP levels during the first week, a longitudinal analysis using a general linear model (GLIM) for repeated measures was used to test the variation of markers levels over time within and between groups. A Kaplan-Meier survival analysis was used to compare 28-day survival between patients with and without LBP increase at 48 hours of study enrollment. Finally, to validate and compare the LBP serum levels as a possible biomarker, receiver operator characteristic (ROC) curves and the area under the curves (AUC) were computed to determine the sensitivity/specificity pairs corresponding to particular LBP levels and APACHE II scores for the discrimination between survivors and non-survivors. Data were analyzed by using SPSS 15.0 for windows (SPSS Inc, Chicago, IL). A two-tailed P value<0.05 was considered significant.
###end p 26
###begin title 27
Results
###end title 27
###begin p 28
###xml 97 104 97 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006818-t001">Table 1</xref>
###xml 614 621 610 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006818-t001">Table 1</xref>
###xml 16 24 <span type="species:ncbi:9606">patients</span>
###xml 176 184 <span type="species:ncbi:9606">Patients</span>
We enrolled 180 patients with severe sepsis. Main characteristics of the cohort are presented in Table 1. Mean age was 63.3+/-15 years and mean APACHE II score was 23.2+/-6.8. Patients had been hospitalized a median of 1 day (IQR: 0-7 days) prior to ICU admission and 54.4% had severe sepsis on ICU admission. Peritonitis was the leading cause of severe sepsis followed by pneumonia. Blood cultures were negative in 49.5% of cases. Most commonly isolated microorganisms were Gram-negative bacteria. Fifty-five percent developed ARDS and 31.1% developed ALI during hospitalization. Overall ICU mortality was 41.1% (Table 1).
###end p 28
###begin title 29
###xml 28 36 <span type="species:ncbi:9606">patients</span>
Main characteristics of 180 patients with severe sepsis.
###end title 29
###begin p 30
APACHE: Acute Physiology and Chronic Health Evaluation; SOFA: sequential organ failure assessment; ICU: intensive care unit; ARDS: acute respiratory distress syndrome; ALI: acute lung injury.
###end p 30
###begin p 31
###xml 1274 1275 1184 1185 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1307 1314 1217 1224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0006818-t002">Table 2</xref>
###xml 1066 1074 <span type="species:ncbi:9606">patients</span>
###xml 1196 1204 <span type="species:ncbi:9606">patients</span>
###xml 1317 1325 <span type="species:ncbi:9606">Patients</span>
The mean baseline LBP serum level was 122.5+/-74 microg/mL (range 26.9-334.0 microg/mL) without significant differences between age, gender, APACHE II score or source of infection. There were no statistical differences of LBP levels in relation to the causative pathogens at study entry: gram-negative infections (136.1+/-82.8), gram-positive infections (126.4+/-72.0 microg/ml), fungal infections (96.5+/-53.7 microg/ml), polymicrobial infections (135.2+/-73.0 microg/ml) (p = 0.385); at 48 hours: gram-negative infections (91.8+/-66.3 microg/ml), gram-positive infections (81.7+/-61.5 microg/ml), fungal infections (62.9+/-26.3 microg/ml), polymicrobial infections (105.5+/-63.2 microg/ml) (p = 0.714); and at 7 days: gram-negative infections (76.9+/-45.8 microg/ml), gram-positive infections (72.7+/-68.2 microg/ml), fungal infections (40.4+/-27.9 microg/ml), polymicrobial infections (69.6+/-49.2 microg/ml) (p = 0.865).Mean LBP levels decreased at 48 hours (93.7+/-66.8 microg/mL) and at day-7 (73.0+/-52.4 microg/mL). This decrease was significantly larger in patients who survived and in those who did not develop ARDS. The largest differences in LBP levels were found at 48 hours between patients who developed ARDS and ALI, and between survivors and non-survivors (P<0.0001, for both comparisons) (Table 2). Patients developing ARDS had the highest values of LBP.
###end p 31
###begin title 32
###xml 23 31 <span type="species:ncbi:9606">patients</span>
LBP serum levels among patients with different degrees of lung injury and in ICU survivors and non-survivors.
###end title 32
###begin p 33
Values are expressed as mean+/-SD in microg/mL. LBP: lipopolysaccharide binding protein; ARDS: acute respiratory distress syndrome; ALI: acute lung injury; ICU: intensive care unit.
###end p 33
###begin p 34
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
P- value from one way ANOVA.
###end p 34
###begin p 35
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 14 15 14 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
P- value from t-test.
###end p 35
###begin p 36
###xml 146 147 146 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 156 164 156 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006818-g001">Figure 1</xref>
###xml 856 857 854 855 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 876 877 874 875 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 901 902 899 900 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 934 935 932 933 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 982 983 980 981 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 198 206 <span type="species:ncbi:9606">patients</span>
###xml 254 262 <span type="species:ncbi:9606">patients</span>
###xml 286 294 <span type="species:ncbi:9606">patients</span>
###xml 338 346 <span type="species:ncbi:9606">patients</span>
###xml 359 367 <span type="species:ncbi:9606">patients</span>
###xml 403 411 <span type="species:ncbi:9606">patients</span>
###xml 424 432 <span type="species:ncbi:9606">patients</span>
###xml 475 483 <span type="species:ncbi:9606">patients</span>
###xml 495 503 <span type="species:ncbi:9606">patients</span>
###xml 529 537 <span type="species:ncbi:9606">patients</span>
###xml 643 651 <span type="species:ncbi:9606">patients</span>
###xml 715 723 <span type="species:ncbi:9606">patients</span>
The GLIM test for repeated measures showed that LBP levels during the first week of severe sepsis clearly separated survivors from non-survivors (P<0.013) (Figure 1). The initial sample size of 180 patients at study entry was subsequently reduced to 147 patients at 48 hours and to 100 patients after one week due to either ICU death (16 patients at 48 h, 22 patients at day-7), ICU discharge alive (10 patients at 48 h, 26 patients at day-7) and/or non-available samples (7 patients at 48 h, 1 patients at day-7). We noted that patients with an ICU stay less than 48 hours had a higher mortality rate (57.6%, 19 out of 33) than the remaining patients in the study (37.4%, 55 out of 147) (p = 0.033). However, when patients with <48 hours ICU stay were compared to those with >/=48 hours ICU stay, there were no significant differences with regard to age (P = 0.457), gender (P = 0.205), lung injury (P = 0.248), source of infection (P = 0.446), or LBP serum levels at study entry (P = 0.792).
###end p 36
###begin title 37
###xml 24 32 <span type="species:ncbi:9606">patients</span>
LBP serum levels in 180 patients with severe sepsis during the first week in the ICU.
###end title 37
###begin p 38
###xml 102 103 100 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Data are reported as mean (+/-SE). LPB: lipopolysaccharide-binding protein; ICU: intensive care unit. P-value was obtained using a general linear model.
###end p 38
###begin p 39
###xml 88 97 88 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0006818.s001">Figure S1</xref>
###xml 99 122 99 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">see supporting material</italic>
###xml 351 359 <span type="species:ncbi:9606">patients</span>
###xml 495 502 <span type="species:ncbi:9606">patient</span>
IL-6, IL-1-beta, IL-10, and CRP levels in survivors and non survivors are summarized in Figure S1 (see supporting material). Using the same analyses that we used for LBP, none of those 4 biomarkers showed statistically significant differences among survivors and non-survivors across days examined. Furthermore, since the sample size of the subset of patients in whom we measured these additional markers was smaller (107 vs. 180 for LBP), for each of these markers we generated a simulated 180 patient dataset increasing artificially their sample size by adding measures from 73 randomly selected cases by resampling. Despite this correction, no statistical significant differences were found between survivors and non-survivors. For IL-6 (the marker with best significance level), the significance levels were p = 0.281 at study entry, p = 0.347 at 48 hours, and p = 0.082 at 7 days.
###end p 39
###begin p 40
###xml 20 28 20 28 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006818-g002">Figure 2</xref>
###xml 220 221 220 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 289 290 289 290 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 358 359 358 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
ROC curves and AUC (Figure 2) showed that LBP serum levels at 48 hours were a better predictor of outcome than the APACHE II score calculated within the first 24 h after ICU admission. The significance for APACHE II was P = 0.016 (AUC: 0.62; 95% CI: 0.52-0.71), for LBP at study entry was P = 0.173 (AUC: 0.57; 95% CI: 0.47-0.66) and for LBP at 48 hours was P<0.0001 (AUC: 0.71; 95%CI: 0.61-0.80).
###end p 40
###begin title 41
Receiver operator characteristic (ROC) curves for discriminating survivors from non-survivors.
###end title 41
###begin p 42
Curves were obtained according to lipopolysaccharide-binding protein (LBP) serum levels at study entry and at 48 h. ROC results using APACHE II scores on the day of ICU admission are also plotted for comparison. APACHE: Acute Physiology and Chronic Health Evaluation; ICU: intensive care unit.
###end p 42
###begin p 43
###xml 328 329 320 321 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 338 346 330 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006818-g003">Figure 3</xref>
###xml 549 550 541 542 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 719 720 711 712 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 732 740 724 732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0006818-g004">Figure 4</xref>
###xml 20 28 <span type="species:ncbi:9606">patients</span>
###xml 182 190 <span type="species:ncbi:9606">patients</span>
###xml 642 650 <span type="species:ncbi:9606">patients</span>
We noted that in 39 patients, LBP serum levels increased at 48 hours compared to baseline (mean increase 49.7 microg/mL) and their mortality was significantly higher than in the 108 patients in whom LBP decreased (mean decrease -52.9 microg/ml) [mortality 61.5% vs. 28.7%, respectively; odds ratio (OR) 3.97; 95% CI: 1.85-8.57, P<0.001] (Figure 3). Even after adjusting for age, gender, number of failing organs, and APACHE II score, an increase of LBP at 48 hours continued to predict a higher mortality risk (adjusted OR: 2.76; 95% CI: 1.16-6.54, P = 0.018).Kaplan-Meier 28-day survival curves showed strong significant differences between patients with or without increases in LBP levels at 48 hours (log rank test, P = 0.0001) (Figure 4).
###end p 43
###begin title 44
###xml 42 50 <span type="species:ncbi:9606">patients</span>
Percentage of survivors and non-survivors patients with severe sepsis according to changes in LBP levels after 48 h of enrolment.
###end title 44
###begin p 45
###xml 41 42 41 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
LPB: lipopolysaccharide-binding protein. P-value was obtained using chi-square test.
###end p 45
###begin title 46
###xml 52 60 <span type="species:ncbi:9606">patients</span>
Kaplan-Meier curves for 28-day survival analysis of patients with severe sepsis.
###end title 46
###begin p 47
###xml 20 28 <span type="species:ncbi:9606">patients</span>
###xml 134 142 <span type="species:ncbi:9606">patients</span>
In continuous line, patients in which lipopolysaccharide-binding protein (LBP) serum levels increased at 48 h; in discontinuous line, patients in which LBP did not increase at 48 h.
###end p 47
###begin title 48
Discussion
###end title 48
###begin p 49
###xml 446 450 446 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Prucha1">[13]</xref>
###xml 452 456 452 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Sakr1">[22]</xref>
###xml 650 654 650 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Prucha1">[13]</xref>
###xml 656 660 656 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Sablotzki1">[19]</xref>
###xml 662 666 662 666 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Sakr1">[22]</xref>
###xml 668 672 668 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Zweigner1">[29]</xref>
###xml 673 677 673 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Martin1">[31]</xref>
###xml 282 290 <span type="species:ncbi:9606">patients</span>
###xml 496 504 <span type="species:ncbi:9606">patients</span>
The main finding of this study is that changes in LBP serum levels at 48 hours after the onset of severe sepsis were associated with disease severity and outcome. Our findings indicate that serial LBP serum measurements may offer a clinically useful biomarker for identification of patients, with severe sepsis, having the worst outcomes and the highest probability of developing sepsis-induced ARDS. In our study, as well as in previous studies [13], [22], serum LBP levels did not differ among patients with gram-negative, gram-positive or fungal infections. The mean LBP serum levels in our series are within the same range as in previous reports [13], [19], [22], [29]-[31].
###end p 49
###begin p 50
###xml 14 18 14 18 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Blairon1">[20]</xref>
###xml 299 303 299 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Prucha1">[13]</xref>
###xml 734 738 734 738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Sakr1">[22]</xref>
###xml 933 937 933 937 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Prucha1">[13]</xref>
###xml 939 943 939 943 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Gani1">[16]</xref>
###xml 945 949 945 949 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Gani3">[30]</xref>
###xml 1234 1238 1234 1238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Sakr1">[22]</xref>
###xml 96 104 <span type="species:ncbi:9606">patients</span>
###xml 423 431 <span type="species:ncbi:9606">patients</span>
###xml 566 574 <span type="species:ncbi:9606">patients</span>
###xml 675 683 <span type="species:ncbi:9606">patients</span>
###xml 818 826 <span type="species:ncbi:9606">patients</span>
###xml 844 852 <span type="species:ncbi:9606">patients</span>
###xml 924 932 <span type="species:ncbi:9606">patients</span>
###xml 1050 1058 <span type="species:ncbi:9606">patients</span>
###xml 1164 1172 <span type="species:ncbi:9606">patients</span>
###xml 1486 1494 <span type="species:ncbi:9606">patients</span>
Blairon et al [20] measured LBP serum levels daily until day 5 or death in a small sample of 24 patients with severe sepsis, but they were unable to demonstrate any correlation between LBP levels and severity, as defined by APACHE II, lung injury and multiple organ dysfunction scores. Prucha et al [13] assessed LBP levels at study entry and at 3- to 5-day intervals for 30 days or until death in a mixed population of 68 patients with systemic inflammatory response, sepsis or septic shock. However, they did not find significant differences in LBP levels between patients with systemic inflammatory response and sepsis or between survivors and non-survivors, since only 9 patients had severe sepsis and/or septic shock. Sakr et al [22] measured the time course of LBP levels in a mixed sample of 327 critically ill patients in which only 55 patients had severe sepsis. As in other previous studies with limited number of patients [13], [16], [30], they found that during the first two days of the disease process LBP concentrations were higher in patients with severe sepsis than in those without sepsis, although no further differences between these groups of patients were observed after the second day. Additionally, Sakr et al [22] concluded that the maximum LBP serum concentration during the first 3 days in the ICU discriminated between survivors and non-survivors, but they were unable to determine if such levels could discriminate between survivors and non survivors among patients with severe sepsis because of the limited sample size (n = 55).
###end p 50
###begin p 51
###xml 24 28 24 28 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Opal1">[17]</xref>
###xml 302 306 302 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Prucha1">[13]</xref>
###xml 308 312 308 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Sakr1">[22]</xref>
###xml 314 318 314 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Zweigner1">[29]</xref>
###xml 594 597 594 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Engel1">[2]</xref>
###xml 599 603 599 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Padkin1">[32]</xref>
###xml 604 608 604 608 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Blanco1">[35]</xref>
###xml 964 968 964 968 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-FisherCJ1">[36]</xref>
###xml 1480 1484 1480 1484 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Blanco1">[35]</xref>
###xml 1640 1644 1640 1644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-FisherCJ1">[36]</xref>
###xml 2969 2973 2969 2973 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Martin2">[37]</xref>
###xml 141 149 <span type="species:ncbi:9606">patients</span>
###xml 769 777 <span type="species:ncbi:9606">patients</span>
###xml 900 905 <span type="species:ncbi:9606">human</span>
###xml 943 951 <span type="species:ncbi:9606">patients</span>
###xml 1088 1096 <span type="species:ncbi:9606">patients</span>
###xml 1268 1276 <span type="species:ncbi:9606">patients</span>
###xml 1389 1397 <span type="species:ncbi:9606">patients</span>
###xml 1427 1435 <span type="species:ncbi:9606">patients</span>
###xml 1518 1525 <span type="species:ncbi:9606">patient</span>
###xml 1662 1670 <span type="species:ncbi:9606">patients</span>
###xml 1730 1738 <span type="species:ncbi:9606">patients</span>
###xml 1883 1891 <span type="species:ncbi:9606">patients</span>
###xml 2176 2183 <span type="species:ncbi:9606">patient</span>
###xml 2403 2411 <span type="species:ncbi:9606">patients</span>
###xml 2436 2443 <span type="species:ncbi:9606">patient</span>
###xml 2460 2468 <span type="species:ncbi:9606">patients</span>
###xml 2822 2830 <span type="species:ncbi:9606">patients</span>
###xml 3240 3247 <span type="species:ncbi:9606">patient</span>
###xml 3296 3303 <span type="species:ncbi:9606">patient</span>
The study by Opal et al [17] is the only published report with a sample size comparable to our study. They measured LBP plasma levels in 253 patients with severe sepsis and/or septic shock and reported mean LBP levels in the lower range of those not only in our series but also in other recent reports [13], [22], [29]. They found that LBP levels were less elevated in non-survivors than survivors. Although the mean APACHE II score in their series was similar to our series, the mortality of their cohort was lower (32.4%) than in our series or that reported in recent epidemiological studies [2], [32]-[35]. Several differences could explain the discrepancies between the two studies. First, the study by Opal et al was a secondary analysis of a population of septic patients selected from the placebo arm of a phase III randomized controlled trial to define the safety and efficacy of recombinant human interleukin 1 receptor antagonist in patients with sepsis [36]. Second, it is plausible that a selection bias occurred since the strict inclusion and exclusion criteria would select patients who were more likely to benefit by the drug under investigation. The observational and non-therapeutic nature of our study design allowed the inclusion of all consecutive patients meeting the criteria for severe sepsis with virtually no exclusion criteria, and therefore, we believe that our patients more closely represent those patients with severe sepsis managed in a routine ICU [35]. The later would explain why our patient population was sicker than the Opal et al. Third, the placebo (control) group in the parent paper by Fisher et al [36] consisted of 302 patients, from which (according to Table 4 in their paper) only 187 patients (62%) had dysfunction of one or more organs, a necessary criteria for being diagnosed as having severe sepsis. However, Opal et al included 253 patients out of those 302 (84%) as having severe sepsis. Forth, although the mean APACHE II score in the Opal et al study was apparently similar to our cohort (26 vs. 23), the magnitude of the standard deviations in both studies (13.6 vs. 6.8, respectively) showed more heterogeneity in their patient population than in our cohort (p = 0.005). Fifth, we do not have much information regarding the prevalence of acute respiratory failure and the use of mechanical ventilation in the Opal study. They reported that 27% of patients had ARDS whereas in our patient population, all patients were mechanically ventilated and 55% had ARDS. We are not surprised by the high prevalence of acute lung dysfunction in our series of severe sepsis since sepsis is the most common clinical condition associated with the development of ARDS and this relationship increases with sepsis severity. In addition, it has been reported that in more than half of patients with severe sepsis without ARDS there is an increased extravascular lung water content, representing subclinical and clinical lung injury [37]. Lastly, there is no enough information on how LBP assays were performed in the Opal et al paper to allow a comparison with our study. Since the data and blood sample collection in the two studies are separated by 15 years, we should acknowledge that differences in patient care, ICU admission policies, the nature of the patient mix, the use of retrospective analysis of data, methods of blood collection and shipping and the technology for LBP assays could explain discrepancies in the reported LBP values.
###end p 51
###begin p 52
###xml 412 416 412 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Martin1">[31]</xref>
###xml 677 681 677 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Cunningham1">[38]</xref>
###xml 1183 1187 1175 1179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Martin1">[31]</xref>
###xml 1189 1193 1181 1185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Cunningham1">[38]</xref>
###xml 145 153 <span type="species:ncbi:9606">patients</span>
###xml 193 201 <span type="species:ncbi:9606">patients</span>
###xml 493 501 <span type="species:ncbi:9606">patients</span>
###xml 617 625 <span type="species:ncbi:9606">patients</span>
###xml 756 764 <span type="species:ncbi:9606">patients</span>
###xml 1315 1323 <span type="species:ncbi:9606">patients</span>
###xml 1385 1393 <span type="species:ncbi:9606">patients</span>
Our study is the first to report an association between LBP levels and severity of respiratory dysfunction and between LBP levels and outcome in patients with sepsis-induced ARDS. Only 19 ARDS patients were diagnosed during the first 48-hour of study entry; the rest were diagnosed later during ICU hospitalization. Thus, in most cases, the worsening of pulmonary dysfunction followed LBP increase. Martin et al [31] measured LBP concentrations in the bronchoalveolar lavage fluid (BAL) of 82 patients with ARDS. Although they found that LBP increased markedly in the BAL, LBP values were similar in all subgroups of patients and were not related to survival. Cunningham et al [38] assessed time-dependent changes in LBP serum concentrations in 121 trauma patients on hospital admission and at 24 h. In this very low-mortality group (16.3%), a significant increase in LBP concentration was observed at 24 h (28.0+/-25.3 vs.72.3+/-45.7 microg/mL). However, although baseline LBP levels were significantly greater in non-survivors than in survivors, after controlling for age and disease severity, LBP concentration did not predict survival. The major difference between those studies [31], [38] and ours is that they measured LBP levels within the first 24 h of admission to the ICU in a heterogeneous population of patients, whereas we performed serial measurements in a population of patients with the same clinical condition (severe sepsis).
###end p 52
###begin p 53
###xml 63 67 63 67 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Prucha1">[13]</xref>
###xml 69 73 69 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Gani1">[16]</xref>
###xml 75 79 75 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Opal1">[17]</xref>
###xml 81 85 81 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Sablotzki1">[19]</xref>
###xml 86 90 86 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Sakr1">[22]</xref>
###xml 92 96 92 96 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Zweigner1">[29]</xref>
###xml 98 102 98 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Gani3">[30]</xref>
###xml 104 108 104 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Cunningham1">[38]</xref>
###xml 1126 1129 1118 1121 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LBP</italic>
###xml 1135 1138 1127 1130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Villar1">[3]</xref>
###xml 1140 1144 1132 1136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Hubacek1">[39]</xref>
###xml 1145 1149 1137 1141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Flores1">[41]</xref>
###xml 1273 1277 1265 1269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Flores1">[41]</xref>
###xml 1372 1375 1364 1367 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LBP</italic>
###xml 418 426 <span type="species:ncbi:9606">patients</span>
###xml 652 660 <span type="species:ncbi:9606">patients</span>
###xml 731 739 <span type="species:ncbi:9606">patients</span>
###xml 1003 1011 <span type="species:ncbi:9606">patients</span>
###xml 1170 1178 <span type="species:ncbi:9606">patients</span>
###xml 1461 1469 <span type="species:ncbi:9606">patients</span>
In general, our findings and those from other previous reports [13], [16], [17], [19]-[22], [29], [30], [38] support the important role that LBP plays in host-defense during sepsis. In the current study, the variation of LBP concentrations at 48 h predicted worsening acute lung injury and death. We postulate that changes in biomarker levels during the course of severe sepsis may enable physicians to identify those patients who are most at risk for deterioration and who are in greatest need of early intervention. A close examination of changes in LBP serum levels at 48 h and their correlation with outcome enabled us to identify a subgroup of 39 patients (21.7%) in which significantly worse outcomes were observed. In those patients, rather than decreasing LBP levels at 48 h, as expected, the serum concentrations were higher than at onset [Note that these increments were not small (median: 49.7 microg/mL; IQR: 15.1-63.3 microg/mL)]. We cannot explain this finding but can speculate why these patients progressed toward a fatal outcome. During sepsis, LBP levels are modified by polymorphic genetic variation of the LBP gene [3], [39]-[41], predisposing these patients to excessive inflammation during an infection and contributing to a poor outcome. Chien et al [41] have recently reported that the presence of a common variant in the 5' flanking region of the LBP gene was correlated with basal LBP serum levels in healthy controls and mortality in patients after allogeneic hematopoietic cell transplantation.
###end p 53
###begin p 54
###xml 704 708 704 708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Polderman1">[42]</xref>
###xml 832 836 832 836 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Tunnell1">[43]</xref>
###xml 924 928 924 928 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Suistomaa1">[44]</xref>
###xml 1010 1014 1010 1014 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Knaus1">[26]</xref>
###xml 1212 1220 <span type="species:ncbi:9606">patients</span>
###xml 1344 1352 <span type="species:ncbi:9606">patients</span>
###xml 1462 1469 <span type="species:ncbi:9606">patient</span>
###xml 1951 1959 <span type="species:ncbi:9606">patients</span>
In our study, the changes in the systemic levels of IL-6, IL-1-beta, IL-10, and CRP were unable to discriminate survivors from non survivors during the first week of severe sepsis. In addition, LBP levels at 48 h performed better than APACHE II in predicting ICU outcome. The ROC curve showed that LBP at 48 h dominates APACHE II for any given sensitivity or specificity threshold. The APACHE II requires collection of data regarding numerous variables over a period of time (during the first 24 hours of ICU admission) taking into account the most abnormal values, relies on laboratory data that may be not uniformly collected, and its use is limited by significant inter- and intraobserver variability [42]. It has been reported that several factors influence the performance of severity of illness scoring system: lead time bias [43], case mix, pre-ICU or ICU management, sampling rate of laboratory and hemodynamic data [44], and novel advances in ICU care and therapy since scoring systems were described [26]. On the other hand, it is important to emphasize that the APACHE II score was developed to predict mortality in general ICU population using data during the first 24 hours of ICU stay. On average, patients from our study met severe sepsis criteria almost 2 days after ICU admission and we did not calculate APACHE II at the time patients met criteria for severe sepsis since it is unknown whether the use of APACHE scores generated at the time of patient enrolment result in under or over performance of APACHE II. We speculate that the main reason behind APACHE II not being a good predictor in severe sepsis could be due to APACHE II is a general purpose severity of disease classification system while LBP serum levels might have a more specific association with severe sepsis. Since APACHE II includes many physiological measurements that are not related with sepsis, it is plausible that it does not perform as well on a cohort of patients with severe sepsis in whom the main cause of death (multiple organ dysfunction) is attributed mainly to one factor (severe infection).
###end p 54
###begin p 55
###xml 535 539 535 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Herrera1">[45]</xref>
###xml 540 544 540 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Gharib1">[47]</xref>
###xml 579 583 579 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Wurfel1">[48]</xref>
It is unlikely that the multifaceted nature of severe sepsis or ARDS would be only monitored with the use of a single biomarker. Microarray-based genome-wide gene expression analysis have shown in animal models that the induction of systemic inflammation by sepsis can cause synergistic effects with acute lung injury in the setting of mechanical ventilation, suggesting that molecules related to the innate immune pathway recognizing the endotoxin might be regulated as well in the presence of lung injury in the absence of infection [45]-[47]. In a recent metaanalysis, Wurfel [48] has indicated that across the different experiments, the most clearly overrepresented theme was "responses to pathogens", noting that the selected genes for the final analyses were identified as differentially regulated in the presence of injury by mechanical ventilation alone. Given this evidence, and since our study have not been designed to answer the question of whether the LBP response is specific or typical of many acute phase proteins, we suggest that the response is, most likely, non-specific.
###end p 55
###begin p 56
###xml 1351 1355 1351 1355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Kalil1">[49]</xref>
###xml 301 309 <span type="species:ncbi:9606">patients</span>
###xml 396 404 <span type="species:ncbi:9606">patients</span>
###xml 498 506 <span type="species:ncbi:9606">patients</span>
###xml 1199 1207 <span type="species:ncbi:9606">patients</span>
###xml 1514 1522 <span type="species:ncbi:9606">patients</span>
###xml 1591 1596 <span type="species:ncbi:9606">human</span>
There are some limitations to our study. First, confirmatory studies with large sample sizes are required to validate this study. Second, despite the fact that changes in mean LBP levels discriminated survivors from non-survivors, our findings cannot define a cut-off point to clearly identify septic patients at 48 h who will survive from those who will not survive, nor clearly identify septic patients who will develop ARDS from those who will not develop it. Third, a drop off in the number of patients at 48 h (from 180 to 147) could affect the overall significance. However, we do not think that this event would have a major effect on the utility of LBP levels as a prognostic biomarker. It is plausible that those who died within the first 48 h had higher levels of serum LBP in the hours that preceded death, making the overall significance even greater if those values were considered at 48 h. Forth, different therapeutic regimes could influence the LBP values and their associated outcome. However, since it was beyond the scope of this study, we do not know whether treatment-dependent variables may influence the performance of our model under different practice patterns. None of the patients in this cohort received activated protein C or low doses of corticosteroids as an adjunctive treatment. As Kalil et al have recently evaluated [49], the strength of statistical and clinical evidence is weak for most clinical trials on therapies that have been recommended in recent guidelines for treating patients with severe sepsis, particularly for low dose steroids, recombinant human activated protein C, and early goal-directed therapy. Those authors have stated that it is essential to replicate those trials in confirmatory studies before guidelines can be fully adopted by clinicians. In fact, a new PROWESS trial is currently underway to test (and validate) the effects of activated protein C in a high risk septic population.
###end p 56
###begin p 57
###xml 134 138 134 138 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0006818-Minter1">[50]</xref>
Our findings add additional justification for evaluating LBP in various high-risk populations during clinical trials. As Minter et al [50] have recently suggested, biomarkers may ultimately serve as targets for future therapeutic trials in severe sepsis whereas it seems essential to choose a biomarker defining appropriate high-risk populations in whom the initial immune inflammatory response is amplified beyond the threshold that is tolerated by the host. Serial monitoring of LBP serum levels may be an appropriate biomarker for subgroup selection and guiding of therapy. We also anticipate that pharmacologic modulation of LBP activation may represent a novel target for future therapeutic trials in the setting of severe sepsis.
###end p 57
###begin p 58
###xml 227 235 <span type="species:ncbi:9606">patients</span>
In summary, the current study constitutes a step forward over previous published studies investigating the potential use of LBP as a biomarker in sepsis. We have found that a distinct pattern of elevated serum levels of LBP in patients with severe sepsis is strongly associated with increased mortality and the development of ARDS. Additional study is necessary, however, before this or any biomarker can be used to predict outcome in severe sepsis.
###end p 58
###begin title 59
Supporting Information
###end title 59
###begin p 60
###xml 69 77 <span type="species:ncbi:9606">patients</span>
Comparison of serum levels of IL-6, IL-1-beta, IL-10, and CRP in 107 patients with severe sepsis during the first week in ICU. Data are reported as mean (+/-SE). IL: interleukin; CRP: C-reactive protein; ICU: intensive care unit. P-value was obtained using GLIM.
###end p 60
###begin p 61
(0.49 MB TIF)
###end p 61
###begin p 62
Click here for additional data file.
###end p 62
###begin p 63
GEN-SEP investigators are:
###end p 63
###begin p 64
###xml 9 12 9 12 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a,b</sup>
###xml 24 25 24 25 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 37 38 37 38 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 47 50 47 50 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b,d</sup>
###xml 66 69 66 69 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b,e</sup>
###xml 83 84 83 84 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">e</sup>
###xml 94 95 94 95 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">e</sup>
###xml 104 107 104 107 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b,e</sup>
###xml 118 121 118 121 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b,f</sup>
###xml 132 135 132 135 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b,f</sup>
Villar J,a,b Espinosa E,c Sanguesa R,c Muros M,b,d Perez-Mendez L,b,e Maca-Meyer N,e Tejera P,e Flores Cb,e, Blanch L,b,f Artigas A.b,f
###end p 64
###begin p 65
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</sup>
###xml 129 130 129 130 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 174 175 174 175 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 196 197 196 197 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sup>
###xml 229 230 229 230 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">e</sup>
###xml 322 323 322 323 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f</sup>
aMultidisciplinary Organ Dysfunction Evaluation Research Network, Hospital Universitario Dr. Negrin, Las Palmas de Gran Canaria; bCIBER de Enfermedades Respiratorias, Spain; cDept. of Anesthesia, dDept. of Clinical Biochemistry, eUnidad de Investigacion, Hospital Universitario N.S. de Candelaria, Santa Cruz de Tenerife, fCritical Care Center, Corporacio Parc Tauli, Sabadell, Barcelona, Spain.
###end p 65
###begin p 66
GRECIA investigators are:
###end p 66
###begin p 67
###xml 9 12 9 12 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a,b</sup>
###xml 22 23 22 23 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</sup>
###xml 34 35 34 35 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 51 52 51 52 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sup>
###xml 63 64 63 64 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sup>
###xml 73 74 73 74 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sup>
###xml 84 85 84 85 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">e</sup>
###xml 96 97 96 97 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">e</sup>
###xml 107 108 107 108 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f</sup>
###xml 121 122 121 122 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</sup>
###xml 133 134 133 134 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">h</sup>
###xml 146 147 146 147 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</sup>
###xml 158 159 158 159 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</sup>
###xml 169 170 169 170 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">j</sup>
###xml 182 183 182 183 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">j</sup>
###xml 194 195 194 195 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k</sup>
###xml 208 209 208 209 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k</sup>
###xml 220 221 220 221 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k</sup>
###xml 234 235 234 235 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">l</sup>
###xml 245 246 245 246 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sup>
###xml 257 258 257 258 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</sup>
###xml 270 271 270 271 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</sup>
Blanco J,a,b Muriel A,a Sagredo V,c Ballesteros JC,d Taboada F,d Muniz G,d Gandia F,e Bobillo F,e Tamayo L,f Labattut AG,g Collado J,h Valledor M,i Antuna MT,i Lopez MJ,j Cortina JJ,j Saldana T,k Caballero A,k Alvarez T,k De Frutos M,l Guerra J,m Alvarez B,n Sandoval J.n
###end p 67
###begin p 68
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</sup>
###xml 69 70 69 70 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 114 115 114 115 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">c</sup>
###xml 177 178 177 178 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">d</sup>
###xml 236 237 236 237 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">e</sup>
###xml 301 302 301 302 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">f</sup>
###xml 368 369 368 369 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</sup>
###xml 423 424 423 424 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">h</sup>
###xml 481 482 481 482 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">i</sup>
###xml 532 533 532 533 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">j</sup>
###xml 591 592 591 592 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">k</sup>
###xml 650 651 650 651 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">l</sup>
###xml 703 704 703 704 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">m</sup>
###xml 753 754 753 754 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</sup>
aMedicina Intensiva, Hospital Universitario Rio Hortega, Valladolid; bCIBER de Enfermedades Respiratorias, Spain; cMedicina Intensiva Hospital Clinico Universitario, Salamanca; dMedicina Intensiva, Hospital Central de Asturias, Oviedo; eMedicina Intensiva, Hospital Clinico Universitario, Valladolid; fMedicina Intensiva, Hospital Universitario Rio Carrion, Palencia; gMedicina Intensiva, Hospital General de Soria, Soria; hMedicina Intensiva, Complejo Hospitalario de Leon, Leon; iMedicina Intensiva, Hospital San Agustin, Aviles; jMedicina Intensiva, Hospital General de Segovia, Segovia; kMedicina Intensiva, Hospital Virgen de la Concha, Zamora; lMedicina Intensiva, Hospital General Yague, Burgos; mMedicina Intensiva, Hospital de Cabuenes, Gijon; nMedicina Intensiva, Hospital del Bierzo, Ponferrada.
###end p 68
###begin title 69
References
###end title 69
###begin article-title 70
Has the mortality of septic shock changed with time?
###end article-title 70
###begin article-title 71
Epidemiology of sepsis in Germany: results from a national prospective multicenter study.
###end article-title 71
###begin article-title 72
Understanding genetic predisposition to sepsis.
###end article-title 72
###begin article-title 73
Biomarkers of inflammation, coagulation and fibrinolysis predict mortality in acute lung injury.
###end article-title 73
###begin article-title 74
Biomarkers of sepsis: lost in translation?
###end article-title 74
###begin article-title 75
Plasma gelsolin depletion and circulating actin in sepsis - A pilot study.
###end article-title 75
###begin article-title 76
Plasma neutrophil elastase and elafin imbalance is associated with acute respiratory distress syndrome (ARDS) development.
###end article-title 76
###begin article-title 77
###xml 137 145 <span type="species:ncbi:9606">patients</span>
A prospective, multicenter derivation of a biomarker panel to assess risk or organ dysfunction, shock, and death in emergency department patients with suspected sepsis.
###end article-title 77
###begin article-title 78
Structure and function of lipopolysaccharide binding protein.
###end article-title 78
###begin article-title 79
Production of the acute-phase protein lipopolysaccharide binding protein by respiratory type II epitelial cells. Implications for local defense to bacterial endotoxins.
###end article-title 79
###begin article-title 80
###xml 59 64 <span type="species:ncbi:9606">human</span>
Lipopolysaccharide binding protein and serum amyloid A sby human intestinal epithelial cells during the acute phase response1.
###end article-title 80
###begin article-title 81
Monocytes can phagocytose gram-negative bacteria by a CD-14 dependent mechanism.
###end article-title 81
###begin article-title 82
###xml 105 113 <span type="species:ncbi:9606">patients</span>
Significance of lipopolysaccharide binding protein (an acute phase protein) in monitoring critically ill patients.
###end article-title 82
###begin article-title 83
The immunopathogenesis of sepsis.
###end article-title 83
###begin article-title 84
###xml 44 49 <span type="species:ncbi:9606">human</span>
Lipopolysaccharide (LPS)-binding protein in human serum determines the tumor necrosis factor response of monocytes to LPS.
###end article-title 84
###begin article-title 85
Procalcitonin, lipopolysaccharide binding protein, interleukin-6 and C-reactive protein in community-acquired infections and sepsis: a prospective study.
###end article-title 85
###begin article-title 86
###xml 90 98 <span type="species:ncbi:9606">patients</span>
Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock.
###end article-title 86
###begin article-title 87
###xml 27 51 <span type="species:ncbi:1313">Streptococcus pneumoniae</span>
###xml 56 77 <span type="species:ncbi:1280">Staphylococcus aureus</span>
Lipoteichoic acid (LTA) of Streptococcus pneumoniae and Staphylococcus aureus cctivates immune cells via Toll-like receptor (TLR)-2, lipopolysaccharide-binding protein (LBP), and CD14, whereas TLR-4 and MD-2 are not involved.
###end article-title 87
###begin article-title 88
###xml 80 88 <span type="species:ncbi:9606">patients</span>
Lipopolysaccharide binding protein (LBP) and markers of acute-phase response in patients with multiple organ dysfunction syndrome (MODS) following open heart surgery.
###end article-title 88
###begin article-title 89
###xml 51 59 <span type="species:ncbi:9606">patients</span>
Lipopolysaccharide binding protein serum levels in patients with severe sepsis due to gram-positive and fungal infections.
###end article-title 89
###begin article-title 90
New immunological serum markers in bacteraemia: anti-inflammatory soluble CD163, but not proinflammatory high mobility group-box 1 protein, is related to prognosis.
###end article-title 90
###begin article-title 91
Lipopolysaccharide binding protein in a surgical intensive care unit: a marker of sepsis?
###end article-title 91
###begin article-title 92
2001 SCCC/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference.
###end article-title 92
###begin article-title 93
CDC definitions for nosocomial infections.
###end article-title 93
###begin article-title 94
A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group.
###end article-title 94
###begin article-title 95
APACHE II: A severity of disease classification system.
###end article-title 95
###begin article-title 96
The American-European Consensus Conference on ARDS: Definitions, mechanisms, relevant outcomes and clinical trial coordination.
###end article-title 96
###begin article-title 97
Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine.
###end article-title 97
###begin article-title 98
###xml 70 78 <span type="species:ncbi:9606">patients</span>
###xml 157 162 <span type="species:ncbi:9606">human</span>
High concentrations of lipopolysaccharide binding protein in serum of patients with severe sepsis or septic shock inhibit the lipopolysaccharide response in human monocytes.
###end article-title 98
###begin article-title 99
A comparison of high-mobility group-box 1 protein, lipopolysaccharide-binding protein and procalcitonin in severe community-acquired infections and bacteraemia: a prospective study.
###end article-title 99
###begin article-title 100
###xml 109 117 <span type="species:ncbi:9606">patients</span>
Relationship between soluble CD14, lipopolysaccharide binding protein, and alveolar inflammatory response in patients with acute respiratory distress syndrome.
###end article-title 100
###begin article-title 101
Epidemiology of severe sepsis occurring in the first 24 hrs in intensive care units in England, Wales, and Northern Ireland.
###end article-title 101
###begin article-title 102
EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units.
###end article-title 102
###begin article-title 103
Improvement in process of care and outcome after a multicenter severe sepsis educational program in Spain.
###end article-title 103
###begin article-title 104
Incidence, organ dysfunction and mortality in severe sepsis: a Spanish multicentre study.
###end article-title 104
###begin article-title 105
###xml 12 17 <span type="species:ncbi:9606">human</span>
###xml 73 81 <span type="species:ncbi:9606">patients</span>
Recombinant human interleukin-1 receptor antagonist reduces mortality of patients with sepsis syndrome as a function of severity: a randomized, double-blind, placebo-controlled trial.
###end article-title 105
###begin article-title 106
###xml 28 36 <span type="species:ncbi:9606">patients</span>
Extravascular lung water in patients with severe sepsis: a prospective cohort study.
###end article-title 106
###begin article-title 107
Serum lipopolysaccharide-binding protein concentrations in trauma victims.
###end article-title 107
###begin article-title 108
###xml 112 120 <span type="species:ncbi:9606">patients</span>
Gene variants of the bacterial/permeability increasing protein and lipopolysaccharide binding protein in sepsis patients: Gender-specific genetic predisposition to sepsis.
###end article-title 108
###begin article-title 109
Lipopolysaccharide binding protein promoter variants influence the risk for Gram-negative bacteremia and mortality after allogeneic hematopoietic cell transplantation.
###end article-title 109
###begin article-title 110
A quality assessment of genetic association studies supporting susceptibility and outcome in acute lung injury.
###end article-title 110
###begin article-title 111
Interobserver variability in the use of APACHE II scores.
###end article-title 111
###begin article-title 112
The effect of lead time bias on severity of illness scoring, mortality prediction and standardized mortality ratio in intensive care-a pilot study.
###end article-title 112
###begin article-title 113
Sampling rate causes bias in APACHE II and SAPS II scores.
###end article-title 113
###begin article-title 114
Positive end-expiratory pressure modulates local and systemic inflammatory responses in a sepsis-induced lung injury model.
###end article-title 114
###begin article-title 115
Mechanical ventilation affects lung function and cytokine production in an experimental model of endotoxemia.
###end article-title 115
###begin article-title 116
Computational identification of key biological modules and transcription factors in acute lung injury.
###end article-title 116
###begin article-title 117
Microarray-based analysis of ventilator-induced lung injury.
###end article-title 117
###begin article-title 118
Why are clinicians not embracing the results from pivotal clinical trials in severe sepsis? A Bayesian analysis.
###end article-title 118
###begin article-title 119
LPS-binding protein mediates LPS-induced liver injury and mortality in the setting of biliary obstruction.
###end article-title 119
###begin p 120
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: Authors do not have any conflict of interest to declare in relation to this manuscript.
###end p 120
###begin p 121
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: Supported by grants from FUNCIS (37/02) and Ministerio de Ciencia of Spain (SAF 2004-6833). CF was supported by an agreement between Instituto de Salud Carlos III and FUNCIS (EMER07/001) under ENCYT 2015 framework. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 121

